Skip to main content
Clinical Trials/NCT03995563
NCT03995563
Unknown
Phase 4

The Effect of Epidural Steroid Use on Pain Relief in Patients With Continuous Epidural Nerve Block in Postherpetic Neuralgia Patients.

Korea University Guro Hospital1 site in 1 country40 target enrollmentMay 15, 2019

Overview

Phase
Phase 4
Intervention
Dexamethasone
Conditions
Neuralgia,Postherpetic
Sponsor
Korea University Guro Hospital
Enrollment
40
Locations
1
Primary Endpoint
VAS score
Last Updated
6 years ago

Overview

Brief Summary

The efficiency of epidural steroid injection in patients who has postherpetic neuralgia is well known. In this study, the purpose is whether the continous epidural steroid injection is effective or not.

Detailed Description

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days. Continous epidural injection will be done during 10 days N group will be injected a 0.19% ropivacaine 8mL only every other day during 10 days

Registry
clinicaltrials.gov
Start Date
May 15, 2019
End Date
November 30, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jung Eun Kim

Assistant professor

Korea University Guro Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients who has herpes zoster
  • Patients has a period (at least 1month) after onset of herpes zoster
  • Patients has a definite symptom along dermatome
  • ASA class I - II
  • Age : 18 - 80 years

Exclusion Criteria

  • Patients who has a cancer
  • Patients who has a neurologic, psychologic, renal, hepatic and hematologic disease
  • Patients who has a other dermatologic disease
  • Patients who has major operation \& procedure history
  • Patients who has a other pain origin
  • Patients who can not be inserted epidural catheter

Arms & Interventions

D group

0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days

Intervention: Dexamethasone

D group

0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days

Intervention: Ropivacaine

N group

0.19% Ropivacaine 8mL only every other day injection during 10 days

Intervention: Ropivacaine

Outcomes

Primary Outcomes

VAS score

Time Frame: up to 10 days

The investigator set the primary outcome If there is a 50% reduction of VAS score.

Study Sites (1)

Loading locations...

Similar Trials